Section Arrow
APLM.NASDAQ
- Apollomics Inc
Quotes are at least 15-min delayed:2026/06/27 15:43 EDT
Regular Hours
Last
 20.8
-1.2 (-5.45%)
Day High 
21.73 
Prev. Close
22 
1-M High
25.1 
Volume 
32.41K 
Bid
18
Ask
22.16
Day Low
19.93 
Open
20 
1-M Low
12.88 
Market Cap 
48.31M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 17.32 
20-SMA 15.7 
50-SMA 14.83 
52-W High 42.12 
52-W Low 3.659 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.57/-0.65
Enterprise Value
48.75M
Balance Sheet
Book Value Per Share
-1.45
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
8.50M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris0.321+0.1152+55.98%-- 
ATAIAtaiBeckley Inc5.29+0.71+15.50%-- 
OCGNOcugen1.5+0.13+9.49%-- 
HUMAHumacyte0.7086+0.0886+14.29%-- 
RXRXRecursion Pharmaceuticals3.52+0.18+5.39%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specificE-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.